Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2003
05/06/2003CA2267093C Composition comprising a liquid absorbed on a support based on precipitate silica
05/06/2003CA2212779C Compositions comprising nanoparticles of nsaid
05/06/2003CA2121674C Biocompatible implant for the timing of ovulation in mares
05/06/2003CA2081408C Composition for the cleaning of teeth and the prophylaxis of caries
05/06/2003CA2047802C Pharmaceutical compositions
05/05/2003WO2002036168A1 Cellulosic particle for pharmaceutical preparation
05/02/2003EP1306219A2 Fluid ejection cartridge and system for dispensing a bioactive substance
05/02/2003EP1306127A1 Method for the preparation of purified microparticles
05/02/2003EP1306083A1 Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion
05/02/2003EP1306082A1 Pressurized metered dose inhalers and pharmaceutical aerosol formulations
05/02/2003EP1306076A2 Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
05/02/2003EP1306072A2 Homogeneous mixtures of silicone oils and organic oils
05/02/2003EP1306071A2 A method and dosage form for dispensing a bioactive substance
05/02/2003EP1305378A1 Medical contact adhesive comprising a two phase adhesive matrix of polyacrylates and polyamine salts
05/02/2003EP1305355A1 Hydrogel films and methods of making and using therefor
05/02/2003EP1305330A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
05/02/2003EP1305329A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
05/02/2003EP1305109A1 Production of polyelectrolyte capsules by surface precipitation
05/02/2003EP1305057A1 Microparticulate biomaterial composition for medical use
05/02/2003EP1305053A1 A medicinal aerosol formulation
05/02/2003EP1305050A2 Improved oral dosage formulations
05/02/2003EP1305049A1 Methods for treating burns on mammalian skin to reduce the risk of infection and to minimize fluid loss
05/02/2003EP1305033A1 Pharmaceutical compositions containing tobramycin and xanthan gum
05/02/2003EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
05/02/2003EP1305021A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
05/02/2003EP1305018A1 Method and compositions for prevention and/or treatment of diabetes and glucose modulation
05/02/2003EP1305012A2 A method for treating celiac disease
05/02/2003EP1305011A1 Compositions and films for capsule manufacture
05/02/2003EP1305010A2 Dosage forms for treatment of oral mycoses
05/02/2003EP1305009A1 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
05/02/2003EP1305008A2 Improved forms of pharmaceutically active agents and method for manufacture thereof
05/02/2003EP1305007A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1305005A2 Microemulsion and micelle systems for solubilizing drugs
05/02/2003EP1305004A1 Embolization using carbon coated particles
05/02/2003EP1304992A1 Topical gel delivery system
05/02/2003EP1304991A1 Method and kit for moisturizing the surface of the eye
05/02/2003EP1304928A2 A positive hydration method of preparing confectionery and the resulting product
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1223951A4 Method of preventing adhesions with absorbable polyoxaesters
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1200064B1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip
05/02/2003EP1171111B1 Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression
05/02/2003EP1140115B1 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
05/02/2003EP1140061B1 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
05/02/2003EP1128730B1 Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type
05/02/2003EP1121375B1 High purity compound (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
05/02/2003EP1109538B1 Anti-inflammatory pharmaceutical formulations
05/02/2003EP1093361B1 Plaster which contains steroids, and a method for the production and use thereof
05/02/2003EP1089712B1 Large porous particles emitted from an inhaler
05/02/2003EP1035891B1 Stereospecific delivery of a drug using electrotransport
05/02/2003EP1028748B1 Compositions providing for increased igf-i solubility
05/02/2003EP1021171B1 Delayed total release gastrointestinal drug delivery system
05/02/2003EP1007014B1 Transdermal, hormone-delivering therapeutic system
05/02/2003EP1001813B1 Pharmaceutical formulations containing voriconazole
05/02/2003EP0998272B1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant
05/02/2003EP0996673B1 Starch-based thermoplastic mixture containing at least one cationic starch and at least one anionic starch, method for producing the mixture, and use of the same
05/02/2003EP0983037B1 Antifungal nail lacquer
05/02/2003EP0973485B1 Cosmetic and dermatological agent with a hard-magnetic particle base
05/02/2003EP0972513B1 Process for preparing emulsified powder
05/02/2003EP0963486B1 Composition containing a humidity regulator, for tissue products
05/02/2003EP0955983B1 Transdermal/transmucosal patch dispenser
05/02/2003EP0941075B1 Rapidly releasing and taste-masking pharmaceutical dosage form
05/02/2003EP0879049B1 Process to prepare soluble delivery systems using volatile salts
05/02/2003EP0874642B1 Sustained release drug formulations
05/02/2003EP0868184B1 Sustained-release microgranules containing diltiazem as the active principle
05/02/2003EP0812187B1 Solid nanoparticulate pharmaceutical composition
05/02/2003EP0801562B1 Pharmaceutical composition containing fenofibrate and polyglycolized glycerides
05/02/2003EP0776194B1 Unilamellar liposomal preparations with high active substance content
05/02/2003EP0772465B1 Alginate fibres, manufacture and use
05/02/2003EP0581849B1 Thiocarbamate sulfoxide composition for deterring ethanol ingestion
05/01/2003WO2003036410A2 Treatment protocol generation for diseases related to angiogenesis
05/01/2003WO2003035876A1 Use of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virus
05/01/2003WO2003035827A2 Plasticized hydrophilic glasses for improved stabilization of biological agents
05/01/2003WO2003035790A2 Improved method for generating an aerosol
05/01/2003WO2003035716A1 Methods of making decomposable thin films of polyelectrolytes and uses thereof
05/01/2003WO2003035668A2 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
05/01/2003WO2003035510A1 Transdermal/transmucosal patch packaging
05/01/2003WO2003035244A1 Method for the preparation of purified microparticles
05/01/2003WO2003035237A2 Compounds for use as surfactants
05/01/2003WO2003035177A2 Optimal polymer mixtures for gastric retentive tablets
05/01/2003WO2003035162A1 Nasal applicator
05/01/2003WO2003035137A2 Method and apparatus for dispensing inhalator medicament
05/01/2003WO2003035136A2 System for administering a drug delivery device
05/01/2003WO2003035114A1 Radiopharmaceutical agent for the treatment of early stage cancer
05/01/2003WO2003035113A1 Magnetic nanodispersion comprising cyclodextrines and method for the production thereof
05/01/2003WO2003035112A1 Enteral nutrient and process for producing the same
05/01/2003WO2003035109A1 Remedies for pruritus
05/01/2003WO2003035107A1 Enzyme inhibitors for inactivating allergens
05/01/2003WO2003035099A1 Biphasic mixtures of glp-1 and insulin
05/01/2003WO2003035092A1 Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
05/01/2003WO2003035089A1 Preventives/remedies for foot and mouth disease
05/01/2003WO2003035080A2 A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
05/01/2003WO2003035069A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003WO2003035063A1 Novel preparation of selective cyclooxygenase ii inhibitors
05/01/2003WO2003035054A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
05/01/2003WO2003035053A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
05/01/2003WO2003035051A2 The use of proton sequestering agents in drug formulations
05/01/2003WO2003035049A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003WO2003035046A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent
1 ... 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 ... 2991